S&P 500   4,285.75 (+0.27%)
DOW   33,964.85 (-0.05%)
QQQ   330.03 (+0.47%)
AAPL   174.59 (+0.02%)
MSFT   291.53 (+0.07%)
META   175.54 (+0.39%)
GOOGL   120.70 (+0.96%)
AMZN   142.67 (+0.40%)
TSLA   917.05 (+0.55%)
NVDA   188.01 (+2.54%)
NIO   19.96 (-0.60%)
BABA   90.78 (+1.13%)
AMD   100.58 (+2.35%)
MU   63.01 (+2.26%)
T   18.46 (+0.22%)
CGC   3.88 (-4.43%)
F   16.06 (+0.19%)
GE   79.58 (-0.43%)
DIS   122.87 (+0.05%)
AMC   20.08 (-5.99%)
PYPL   98.92 (-0.50%)
PFE   49.06 (-0.43%)
NFLX   245.44 (+1.78%)
S&P 500   4,285.75 (+0.27%)
DOW   33,964.85 (-0.05%)
QQQ   330.03 (+0.47%)
AAPL   174.59 (+0.02%)
MSFT   291.53 (+0.07%)
META   175.54 (+0.39%)
GOOGL   120.70 (+0.96%)
AMZN   142.67 (+0.40%)
TSLA   917.05 (+0.55%)
NVDA   188.01 (+2.54%)
NIO   19.96 (-0.60%)
BABA   90.78 (+1.13%)
AMD   100.58 (+2.35%)
MU   63.01 (+2.26%)
T   18.46 (+0.22%)
CGC   3.88 (-4.43%)
F   16.06 (+0.19%)
GE   79.58 (-0.43%)
DIS   122.87 (+0.05%)
AMC   20.08 (-5.99%)
PYPL   98.92 (-0.50%)
PFE   49.06 (-0.43%)
NFLX   245.44 (+1.78%)
S&P 500   4,285.75 (+0.27%)
DOW   33,964.85 (-0.05%)
QQQ   330.03 (+0.47%)
AAPL   174.59 (+0.02%)
MSFT   291.53 (+0.07%)
META   175.54 (+0.39%)
GOOGL   120.70 (+0.96%)
AMZN   142.67 (+0.40%)
TSLA   917.05 (+0.55%)
NVDA   188.01 (+2.54%)
NIO   19.96 (-0.60%)
BABA   90.78 (+1.13%)
AMD   100.58 (+2.35%)
MU   63.01 (+2.26%)
T   18.46 (+0.22%)
CGC   3.88 (-4.43%)
F   16.06 (+0.19%)
GE   79.58 (-0.43%)
DIS   122.87 (+0.05%)
AMC   20.08 (-5.99%)
PYPL   98.92 (-0.50%)
PFE   49.06 (-0.43%)
NFLX   245.44 (+1.78%)
S&P 500   4,285.75 (+0.27%)
DOW   33,964.85 (-0.05%)
QQQ   330.03 (+0.47%)
AAPL   174.59 (+0.02%)
MSFT   291.53 (+0.07%)
META   175.54 (+0.39%)
GOOGL   120.70 (+0.96%)
AMZN   142.67 (+0.40%)
TSLA   917.05 (+0.55%)
NVDA   188.01 (+2.54%)
NIO   19.96 (-0.60%)
BABA   90.78 (+1.13%)
AMD   100.58 (+2.35%)
MU   63.01 (+2.26%)
T   18.46 (+0.22%)
CGC   3.88 (-4.43%)
F   16.06 (+0.19%)
GE   79.58 (-0.43%)
DIS   122.87 (+0.05%)
AMC   20.08 (-5.99%)
PYPL   98.92 (-0.50%)
PFE   49.06 (-0.43%)
NFLX   245.44 (+1.78%)

Arbutus Biopharma - ABUS Stock Forecast, Price & News

$2.40
0.00 (0.00%)
(As of 08/18/2022 11:51 AM ET)
Add
Compare
Today's Range
$2.34
$2.40
50-Day Range
$2.20
$2.92
52-Week Range
$1.93
$6.50
Volume
8,010 shs
Average Volume
919,042 shs
Market Capitalization
$359.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.13

Arbutus Biopharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
196.9% Upside
$7.13 Price Target
Short Interest
Healthy
3.17% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.55mentions of Arbutus Biopharma in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.44) to ($0.64) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.95 out of 5 stars

Medical Sector

821st out of 1,122 stocks

Pharmaceutical Preparations Industry

411th out of 551 stocks

ABUS stock logo

About Arbutus Biopharma (NASDAQ:ABUS) Stock

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Arbutus Biopharma Price Performance

Shares of NASDAQ:ABUS remained flat at $2.40 during mid-day trading on Thursday. The stock had a trading volume of 7,925 shares, compared to its average volume of 919,042. Arbutus Biopharma has a twelve month low of $1.93 and a twelve month high of $6.50. The stock has a market cap of $359.88 million, a P/E ratio of -3.98 and a beta of 2.24. The business's fifty day moving average price is $2.57 and its 200-day moving average price is $2.70.

Arbutus Biopharma (NASDAQ:ABUS - Get Rating) last posted its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.10) EPS for the quarter, beating analysts' consensus estimates of ($0.13) by $0.03. Arbutus Biopharma had a negative net margin of 211.09% and a negative return on equity of 61.57%. During the same period in the prior year, the business posted ($0.23) EPS. As a group, analysts expect that Arbutus Biopharma will post -0.44 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, JMP Securities decreased their price objective on shares of Arbutus Biopharma from $10.00 to $9.00 and set a "market outperform" rating on the stock in a report on Tuesday, June 28th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $7.13.

Receive ABUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arbutus Biopharma and its competitors with MarketBeat's FREE daily newsletter.

ABUS Stock News Headlines

Arbutus to Participate in June Investor Conferences
ABUS Mar 2022 2.500 call
See More Headlines
Receive ABUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arbutus Biopharma and its competitors with MarketBeat's FREE daily newsletter.

ABUS Company Calendar

Last Earnings
8/04/2022
Today
8/18/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ABUS
Employees
85
Year Founded
1992

Price Target and Rating

Average Stock Price Forecast
$7.13
High Stock Price Forecast
$9.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+196.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-76,250,000.00
Net Margins
-211.09%
Pretax Margin
-197.77%

Debt

Sales & Book Value

Annual Sales
$10.99 million
Book Value
$1.02 per share

Miscellaneous

Free Float
142,154,000
Market Cap
$359.88 million
Optionable
Optionable
Beta
2.24

Social Links


Key Executives

  • Mr. William H. Collier (Age 62)
    Pres, CEO & Director
    Comp: $1.03M
  • Mr. David C. Hastings CPA (Age 61)
    CFO & Chief Accounting Officer
    Comp: $647.1k
  • Dr. Michael J. Sofia Ph.D. (Age 64)
    Chief Scientific Officer
    Comp: $670.22k
  • Ms. Lisa M. Caperelli
    VP of Investor Relations
  • Dr. Elizabeth Howard (Age 68)
    Exec. VP, Gen. Counsel, Chief Compliance Officer & Sec.
  • Dr. Gaston Picchio Ph.D. (Age 58)
    Chief Devel. Officer
  • Mr. Michael J. McElhaugh (Age 47)
    Chief Bus. Officer
  • Mr. R. Hector Mackay-Dunn B.A. (Age 71)
    J.D., L.L.B., Q.C, Q.C., Sec.













ABUS Stock - Frequently Asked Questions

Should I buy or sell Arbutus Biopharma stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arbutus Biopharma in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ABUS shares.
View ABUS analyst ratings
or view top-rated stocks.

What is Arbutus Biopharma's stock price forecast for 2022?

4 brokers have issued twelve-month price objectives for Arbutus Biopharma's stock. Their ABUS share price forecasts range from $5.00 to $9.00. On average, they expect the company's share price to reach $7.13 in the next year. This suggests a possible upside of 196.9% from the stock's current price.
View analysts price targets for ABUS
or view top-rated stocks among Wall Street analysts.

How have ABUS shares performed in 2022?

Arbutus Biopharma's stock was trading at $3.89 on January 1st, 2022. Since then, ABUS shares have decreased by 38.3% and is now trading at $2.40.
View the best growth stocks for 2022 here
.

When is Arbutus Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our ABUS earnings forecast
.

How were Arbutus Biopharma's earnings last quarter?

Arbutus Biopharma Co. (NASDAQ:ABUS) posted its earnings results on Thursday, August, 4th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.13) by $0.03. Arbutus Biopharma had a negative trailing twelve-month return on equity of 61.57% and a negative net margin of 211.09%. During the same quarter last year, the firm earned ($0.23) EPS.

What is Mark J. Murray's approval rating as Arbutus Biopharma's CEO?

6 employees have rated Arbutus Biopharma Chief Executive Officer Mark J. Murray on Glassdoor.com. Mark J. Murray has an approval rating of 22% among the company's employees. This puts Mark J. Murray in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Arbutus Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arbutus Biopharma investors own include Ballard Power Systems (BLDP), Chiasma (CHMA), Bausch Health Companies (BHC), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), GW Pharmaceuticals (GWPH), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), TherapeuticsMD (TXMD) and Novavax (NVAX).

What is Arbutus Biopharma's stock symbol?

Arbutus Biopharma trades on the NASDAQ under the ticker symbol "ABUS."

Who are Arbutus Biopharma's major shareholders?

Arbutus Biopharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Hudson Bay Capital Management LP (3.11%), Millennium Management LLC (2.77%), Two Seas Capital LP (2.34%), State Street Corp (1.31%), Northern Trust Corp (0.60%) and Primecap Management Co. CA (0.28%).
View institutional ownership trends
.

How do I buy shares of Arbutus Biopharma?

Shares of ABUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arbutus Biopharma's stock price today?

One share of ABUS stock can currently be purchased for approximately $2.40.

How much money does Arbutus Biopharma make?

Arbutus Biopharma (NASDAQ:ABUS) has a market capitalization of $359.88 million and generates $10.99 million in revenue each year. The biopharmaceutical company earns $-76,250,000.00 in net income (profit) each year or ($0.60) on an earnings per share basis.

When was Arbutus Biopharma founded?

Arbutus Biopharma was founded in 1992.

How can I contact Arbutus Biopharma?

Arbutus Biopharma's mailing address is 701 VETERANS CIRCLE, WARMINSTER PA, 18974. The official website for the company is www.arbutusbio.com. The biopharmaceutical company can be reached via phone at (267) 469-0914, via email at ir@arbutusbio.com, or via fax at 604-419-3201.

This page (NASDAQ:ABUS) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.